Clinical Trial Update: Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 study comparing inhaled Technosphere insulin powder with a subcutaneous rapid-acting insulin analog in individuals with Type 1 diabetes; the study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin inhalation powder) (insulin human inhalation powder)
• Subcutaneous rapid-acting insulin analog (rapid-acting insulin analog)

Snippet

Sponsor: Mannkind Corporation | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED